Wakix (Pitolisant HCl) Patent Expiration, LOE Window & CMS Spending
Wakix (Pitolisant HCl) by Harmony Management: FDA Orange Book core substance LOE 2030-03-07 (last listed 2033-02-13), 3 AB generics, $250.5M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Harmony Management |
| FDA Application & Pathway | N211150 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2030-03-07 |
| Last Listed Patent or Exclusivity Date | 2033-02-13 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 3 |
| 2024 CMS Total Public Spend | $250.5M |
| 2024 Medicare Part D Spend | $132.5M |
| 2024 Medicaid Spend | $118.1M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 22.5% 2-yr change) |